Q3 EPS Forecast for Maze Therapeutics Increased by Analyst

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Equities research analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for Maze Therapeutics in a report issued on Monday, October 5th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.70) per share for the quarter, up from their prior estimate of ($0.77). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.63) EPS, Q1 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.64) EPS, FY2027 earnings at ($2.60) EPS, FY2028 earnings at ($2.23) EPS, FY2029 earnings at ($2.05) EPS and FY2030 earnings at ($2.16) EPS.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76).

MAZE has been the topic of a number of other reports. BTIG Research reiterated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Citigroup initiated coverage on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price for the company. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Finally, TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $63.40.

Maze Therapeutics Trading Down 1.4%

NASDAQ:MAZE opened at $25.88 on Wednesday. Maze Therapeutics has a 12-month low of $21.95 and a 12-month high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock’s 50 day simple moving average is $26.84 and its 200-day simple moving average is $27.42. The firm has a market cap of $1.44 billion, a P/E ratio of -10.27 and a beta of 2.16.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently added to or reduced their stakes in MAZE. Frazier Life Sciences Management L.P. raised its position in Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after acquiring an additional 465,641 shares during the last quarter. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics in the second quarter valued at approximately $133,502,907. ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $122,983,582. BlackRock Inc. purchased a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $104,525,000. Finally, Jupiter Topco LLC acquired a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $101,764,000.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $27.58, for a total value of $206,850.00. Following the sale, the insider owned 26,250 shares of the company’s stock, valued at approximately $723,975. This represents a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the transaction, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at $477,189.79. This trade represents a 65.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 192,991 shares of company stock valued at $5,152,084 in the last ninety days. Corporate insiders own 5.30% of the company’s stock.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Maze’s third and fourth quarters of 2026 to losses of $0.70 and $0.71 per share, respectively, from prior estimates of $0.77 and $0.80. The firm also improved its full-year 2026 forecast to a $2.63 loss from $2.81, while raising its 2027, 2028 and 2029 forecasts to losses of $2.60, $2.23 and $2.05 per share. These changes suggest analysts expect slower cash burn or improved operating performance than previously anticipated. MAZE Stock Gets Increased EPS Forecast from HC Wainwright
• Neutral Sentiment: HC Wainwright reiterated its “Buy” rating and $110 price target. While that target is well above Maze’s recent trading level, the company is still expected to post significant losses, with consensus calling for approximately a $2.72 loss per share for the current year. The analyst also projects losses of $0.65 per share in the first quarter of 2027 and $0.64 in the fourth quarter.
• Negative Sentiment: HC Wainwright sharply reduced its fiscal 2030 EPS forecast to a $2.16 loss from a $0.72 loss previously. The downgrade implies a slower path to profitability in the long term and may limit enthusiasm over the otherwise favorable near- and medium-term estimate revisions.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.